Modelling-Based Prediction of Clinical Benefits from Etravirine in the TMC125-C223 Trial

REFERENCES

• Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348: 2175–2185.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant human immunode-ficiency virus type 1 in Europe and Australia. N Engl J Med. 2003;348:2186–2195.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Lundgren J, Walker A, et al. Predictors of trend in CD4-positive T cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51–62.
   PubMed Web of Science ®Google Scholar
• Delta Coordinating Committee. Delta: a randomised dou-ble-blind controlled trial comparing combinations of zidovu-dine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet. 1996:348(9023):283–291.
   PubMed Web of Science ®Google Scholar
• CAESAR Coordinating Committee Randomised trial of ad-dition of lamivudine or lamivudine plus loviride to zidovu-dine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 1997;349(9063):1413–1421.
   PubMed Web of Science ®Google Scholar
• Murray JS, Elashoff MR, lacono-Connors LC, Cvetkovich TA, Struble KA. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS. 1999;13(7):797–804.
   PubMed Web of Science ®Google Scholar
• Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167–1170.
   PubMed Web of Science ®Google Scholar
• Hill AM, De Masi R, Dawson D. Meta-analysis of antiretro-viral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death. Antivir Ther 1998;3(3):139–145.
   PubMed Web of Science ®Google Scholar
• Holkmann Olsen C, Gate!! J, Ledergerber B, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell counts, in relation to specific antiretroviral drugs in the regimen. AIDS. 2005;19:319–330.
   PubMed Web of Science ®Google Scholar
• Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase in-hibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48(12):4680–4686.
   PubMed Web of Science ®Google Scholar
• Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS. 2003;17(18):F49–54.
   PubMed Web of Science ®Google Scholar
• Cohen C, Steinhart C, Ward D, Ruane P, Peeters M, Woodfall B. 48-week durable efficacy and safety results of TMC125 in HIV patients with NNRTI and PI resistance - Study TMC125-C223. In: Program and abstracts of the British HIV Association; April 2006; Brighton, UK Ab-stract 2.
   Google Scholar
• Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996;335(15):1081–1090.
   PubMed Web of Science ®Google Scholar
• Dolin R, Amato DA, Fisch MA, et al. Zidovudine com-pared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group. Arch Intern Med. 1995;155(9):961–974.
   PubMed Web of Science ®Google Scholar
• Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med. 1992;327(9):581–587.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in per-sons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–733.
   PubMed Web of Science ®Google Scholar
• Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351(9102):543–549.
   PubMed Web of Science ®Google Scholar
• Roche NV 14256 — Roche. Invirase (saquinavir mesylate) prescribing information.
   Google Scholar
• Stel!brink HJ, Hawkins DA, Clumeck N, et al. Randomised, multicentre Phase III study of saquinavir plus zidovudine plus zalcitabine in previously untreated or minimally pre-treated patients. Clin Drug Invest. 2000;20(5):295–307.
   Web of Science ®Google Scholar
• D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A ran-domized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med. 1996;124(12)1 019–1030.
   Web of Science ®Google Scholar
• Suileman J, Lawi D, Ulp D, et al. Indinavir (IDV) alone and with zidovudine (ZDV) in ZDV naïve patients with 50–250 CD4 cells/mm3: surrogate markers. In: Program and ab-stracts of the Eighth European Congress on Clinical Mi-crobiology and Infectious Diseases; May 1997; Lausanne, Switzerland. Abstract 1501.
   Google Scholar
• Suileman J, Lawi D, Ulp D, et al. Indinavir (IDV) alone and with zidovudine (ZDV) in ZDV naïve patients with 50–250 CD4 cells/mm3: clinical efficacy. In: Program and abstracts of the Eighth European Congress on Clinical Microbiology and Infectious Diseases; May 1997; Lausanne, Switzer-land. Abstract 1502.
   Google Scholar
• Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368(9534):466–475.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Quelroz-Telles F, Rockstroh J, et al. TMC114/r provides durable viral load suppression in treatment ex-perienced patients: POWER 1 and 2 combined Week 48 analysis. In: Program and abstracts of the World AIDS Conference; August 2006; Toronto, Canada. Abstract TUAB0104.
   Google Scholar
• Hill AM, Montaner JSG, Smith C. Predicted clinical benefits of TMC114/r from treatment effects on CD4 counts and HIV RNA. HIV Med. In press.
   Web of Science ®Google Scholar
• Grinsztein B, Nguyen B, Katlama C, et al. Potent efficacy of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: Program and abstracts of the 46th ICAAC; September 2006; San Francisco, CA. Abstract H–1670b.
   Google Scholar